glp-1 telehealth crackdown news today FDA issued 25 warning letters to companies for false and misleading claims about compounded products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of The FDA announced plans to

Who Should Avoid GLP-1 Medications

While GLP1 receptor agonists have long been recognized for their glucose-lowering and weight-loss effects, they now offer potential for improving liver outcomes, especially in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) or its more advanced form, metabolic dysfunction-associated steatohepatitis (MASH)

Please note that if you disable cookies on your Internet-enabled device, some parts of the Services may not function properly or offer you the same degree of personalization

The medical spa model has proven particularly effective at normalizing GLP-1 use among demographics that might not otherwise have considered obesity medication